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factors, psychological and medical data, as well as car-
diometabolic markers were assessed with questionnaires 
and patient interviews.  Results: Linear regression models 
showed a significant positive correlation of pain with TGF-β 1 
( b = 770.91,  p = 0.031) and a significant inverse correlation of 
pain with IL-33 ( b = –0.11,  p = 0.015) after controlling for age, 
gender, body mass index, lifetime depression, acute stress 
disorder symptoms, and the prognostic Global Registry of 
Acute Coronary Events (GRACE) score. Pain was not associ-
ated with IL-6 but with the GRACE score ( b = 0.01,  p = 0.003). 
Pain showed no significant association with TNF-α.  Conclu-
sion: Pain during MI was associated with anti- but not proin-
flammatory cytokines. As IL-33 has been shown to be cardio-
protective, lower IL-33 levels with more intense pain may 
suggest a pathway through which increased pain during MI 
may have an impact on the medical prognosis. 
 © 2017 S. Karger AG, Basel 
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 Abstract 
 Objective: Pain and inflammation during acute myocardial 
infarction (AMI) have been associated with the development 
of posttraumatic stress disorder and may also impact nega-
tively on somatic outcome. We investigated the relationship 
between pain during AMI and levels of circulating proinflam-
matory (tumor necrosis factor [TNF]-α, interleukin [IL]-6) and 
anti-inflammatory (IL-33 and tissue growth factor [TGF]-β 1 ) 
cytokines.  Methods: Data were collected as part of the 
Myocardial Infarction – Stress Prevention Intervention (MI-
SPRINT) study. We included 140 patients (mean age 59.6 
years, 82.1% male) with high acute psychological distress 
within 48 h after MI. Fasting blood samples were drawn 
thereafter to measure cytokine levels. Sociodemographic 
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 Introduction 
 Acute myocardial infarction (AMI) is a life-threaten-
ing event during which the majority of patients experi-
ence intense pain  [1] . Pain intensity has been shown to be 
associated with peritraumatic psychological distress  [1] 
and the development of posttraumatic stress in patients 
who suffered MI  [2–5] . Further, pain intensity seems to 
be associated with the clinical outcome in the aftermath 
of MI. A previous study showed that patients who had 
experienced more pain during MI also had a higher risk 
of hospital readmission due to cardiovascular disease 
events during a 32-month follow-up  [6] . Therefore, pain 
during MI may be associated with a poorer prognosis re-
garding mental and physical health.
 Due to hypoxic tissue damage and cell death, several 
pro- and anti-inflammatory processes are triggered dur-
ing AMI. In a first step, an inflammatory reaction serves 
to process and clear damaged tissue  [7] . During this pro-
cess, proinflammatory cytokines like tumor necrosis fac-
tor (TNF)-α, interleukin (IL)-1, and IL-6 are expressed 
 [8] . In a second step, inflammation suppression facilitates 
initiation of myofibroblast proliferation and scarring. 
Molecules of the transforming growth factor (TGF)-β 
family play an important role in regulating this process 
 [8, 9] . Another cytokine that is involved in cardiac re-
modeling is IL-33: it reduces MI volume and improves 
contractile function  [10] . Although proinflammatory ef-
fects have also been attributed to IL-33, IL-33 appears to 
be atheroprotective and might thereby oppose cardiovas-
cular disease progression  [11] . In this paper, we will dis-
cuss IL-33 as an anti-inflammatory cytokine based on in-
vestigations in cardiological patients.
 Not only cardiac tissue injury, but also pain intensity 
and psychological distress may cause an increase in in-
flammation markers during AMI. Both acute and chron-
ic psychosocial stress have been associated with the re-
lease of proinflammatory cytokines, e.g., TNF-α and IL-6 
 [12–15] , and, as mentioned above, pain and acute psy-
chological distress are correlated during AMI.
 Proinflammatory cytokines have been associated with 
impaired psychological and physical health in the long-
term, including posttraumatic stress  [16–19] . In popula-
tion-based studies, IL-6 and TNF-α were both found to 
be associated with increased morbidity and mortality in-
dependent of other risk factors, particularly in men  [20–
22] . Several studies showed an association between worse 
cardiovascular outcome and increased TNF-α  [23] and 
IL-6  [24–26] levels specifically following an acute coro-
nary syndrome (ACS). However, despite their anti-in-
flammatory properties during MI, both IL-33  [27, 28] and 
TGF-β  [29] have been found to be associated with a worse 
prognosis in coronary artery disease.
 To date, little is known about the interplay of pain and 
myocardial damage regulating inflammation in AMI. Since 
pain and inflammation are both predictors of future cardio-
vascular and psychological health, we examined their rela-
tionship during AMI. We hypothesized that stronger pain 
during AMI would be associated with increased levels of 
proinflammatory cytokines TNF-α and IL-6, independent 
of sociodemographic, medical, and psychometric data. Fur-
thermore, we expected a negative association between pain 
and the anti-inflammatory TGF-β 1 and IL-33.
 Patients and Methods 
 Patients and Study Design 
 The present study retrieved data from the randomized-con-
trolled trial Myocardial Infarction – Stress Prevention Interven-
tion (MI-SPRINT), which was conducted between 2012 and 2015. 
The trial included patients who were referred to the Inselspital, 
Bern University Hospital, with AMI, and aimed to test whether 
trauma-focused psychological counseling in this phase could re-
duce the development of posttraumatic stress  [30] . The study pro-
tocol was approved by the ethics committee of the State of Bern, 
Switzerland, and written informed consent was obtained from all 
participants. In addition to confirmed ST elevation MI (STEMI) 
or non-STEMI, further inclusion criteria were age  ≥ 18 years, suf-
ficient knowledge of the German language, stable circulatory con-
ditions, and considerable pain and psychological distress during 
MI (cf. Psychometric Assessments). Specific exclusion criteria 
were severe comorbidity reducing life expectancy to <1 year, cur-
rent severe depression per the cardiologist’s clinical judgment, sui-
cidal ideations during the last 2 weeks, cognitive impairment/dis-
orientation, emergency coronary artery bypass graft surgery, and 
participation in another randomized, controlled clinical trial.
 Within 48 h after hospital admission, participants underwent a 
standardized interview for the assessment of pain perception, 
medical history, and sociodemographic data. They also completed 
the Acute Stress Disorder Scale (ASDS). The following morning, a 
fasting blood sample was drawn to measure circulating biomarker 
concentrations.
 Of 190 patients included, cytokine levels were assessable in 143. 
The most common reasons for missing values were the following: 
unexpected/immediate transfer to other hospitals, blood samples 
could not be processed on weekends, blood sampling was techni-
cally not possible, blood samples or values were lost, or blood sam-
ples were contaminated. In 3 cases, pertinent personal history data 
were lacking due to an unexpected transfer during their hospital 
stay. Data analysis could therefore be conducted on a final sample 
of 140 patients.
 Demographic and Medical Factors 
 We obtained patient characteristics, including age, sex, living 
status, weight and height (to calculate the body mass index [BMI]); 
and medical history by standardized interview questions during 
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admission or from hospital charts. Medical information on the 
number of vessels involved in coronary lumen stenosis >50%, tro-
ponin T peak levels, left ventricular ejection fraction, and other 
parameters necessary to calculate the Global Registry of Acute Cor-
onary Events (GRACE) score was retrieved from hospital charts.
 The GRACE Score 
 The online tool “GRACE 2.0 ACS Risk Calculator” based on the 
revised GRACE algorithms for predicting death or death/myocar-
dial infarction following an initial ACS  [31] was used to calculate 
the GRACE score. The algorithm considers age, heart rate, sys-
tolic blood pressure, Killip class (indicating heart failure in AMI 
patients,  [32] ), initial serum creatinine concentration, positive ini-
tial cardiac markers, cardiac arrest on admission, and presence of 
ST deviation. A score is generated which is related to the occur-
rence of the named adverse outcomes with higher scores indicat-
ing higher risk of occurrence.
 Psychometric Assessment 
 Pain and Acute Psychological Distress 
 Patients were asked to evaluate their most intense pain level 
experienced during AMI (“Please indicate how strong your pain 
was during the heart attack”) on a scale from 0 to 10, with 10 being 
the highest imaginable pain (visual analogue scale for pain  [33] ). 
For inclusion in MI-SPRINT, a score of at least 5 for experienced 
pain and of at least 5 for either fear of dying (“During my referral 
to the hospital, the emergency unit, or the intensive care unit, I was 
afraid I was dying”) and/or helplessness (“When the doctor told 
me I had a heart attack, I was frightened, felt helpless, and was 
afraid of losing control of the situation”) was required.
 ASD Symptoms 
 The German version of the ASDS was used to assess symptoms 
of ASD  [34, 35] . The scale is a self-rating instrument with 19 items to 
be scored on a 5-point Likert scale, from 0 (not at all) to 4 (extreme-
ly). Sum scores range from 0 to 76, with higher values indicating 
more stress. The ASDS consists of the 4 subscales dissociation, reex-
periencing, avoidance, and arousal (DSM IV)  [36] . All participants 
were asked to rate these symptoms with respect to MI. The instru-
ment was validated in a cardiac sample and showed good internal 
consistency (Cronbach α sum score = 0.88)  [35] . Good reliability was 
also achieved in our sample (Cronbach α sum score = 0.84).
 Laboratory Analysis 
 Blood samples were collected into EDTA tubes and centrifuged 
for 10 min at 2,000  g . Plasma was transferred to polypropylene 
tubes and stored at –80  °  C. Concentrations of biomarkers were de-
termined using Luminex technology with magnetic bead-based 
immunoassays (human Th17 cytokine panel and TNF-α, IL-6, IL-
33, TGF-β, and TGF-β 1 assays; Bio-Rad Laboratories Inc., Hercu-
les, CA, USA). Intra- and interassay coefficients of variation were 
<10% for all biomarkers. Detection limits were 0.07 pg/mL 
(TNF-α), 0.67 pg/mL (IL-6), 0.58 pg/mL (IL-33), and 3.9 pg/mL 
(TGF-β 1 ). The levels of lowest quantification (LLOQ) were as fol-
lows: 0.57 pg/mL (TNF-α), 1.65 pg/mL (IL-6), 4.18 pg/mL (IL-33), 
and 1.69 pg/mL (TGF-β 1 ). Fluorescence intensity results were used 
to distinguish nondetectable from nonquantifiable values. Values 
below sensitivity (not detectable) were substituted with half the 
detection limit. Values between sensitivity and LLOQ (not quan-
tifiable) were substituted with half the LLOQ.
 Statistical Analysis 
 Data were analyzed using the PASW 21.0 statistical software 
package (SPSS Inc, Chicago, IL, USA). The level of significance was 
set at  p < 0.05 (2 tailed). Missing items were replaced using the ex-
pectation-maximization algorithm  [37] . Concentrations of TNF-α, 
IL-6, and IL-33 were log transformed to approximate a normal dis-
tribution. Multivariate normality of the data distribution was tested 
using Mahalanobis distance with a level of significance of  p < 0.001. 
To demonstrate patient characteristics, the sample was split into 2 
groups with less (5–7 points) versus more intense pain (8–10 points). 
Pearson χ 2 and independent-sample  t tests for categorical and con-
tinuous variables, respectively, were used to compare both groups on 
demographic and health characteristics. The Mann-Whitney  U test 
was used for group comparisons on BMI, GRACE score, and peak 
troponin level, as these values were not normally distributed.
 We used multivariate linear regression with forced entry of co-
variates to test for an independent contribution of pain levels to 
the concentrations of the assessed cytokines. Variables were added 
to the model in 5 blocks. In a first step, we entered the a priori de-
fined control variables (age and gender). Depression and BMI were 
entered in a 2nd and the GRACE score in a 3rd step. In block 4, the 
ASDS sum score served as a psychometric control variable. Final-
ly, pain was added to the model. For each cytokine, regression 
models were run separately. We did not adjust  p values for multiple 
comparisons because of the prespecified direction of the associa-
tion between pain and cytokine levels.
 Linearity, homoscedasticity, and absence of multicollinearity 
were tested by scatter plot and curve estimation. Durbin Watson 
statistics assured exclusion of autocorrelation. Results are ex-
pressed as unstandardized  b coefficients, standard errors of the 
mean, and changes in  R 2 in each step with  p values.
 Table 1.  Characteristics of the patients stratified by pain severity
Variables Total  Pain score p
 5 – 7 8 – 10
Patients, n
%
140
100
52
37.1
88
62.9
Mean age, years 59.6 58.7 60.1 0.47
Female gender, % 17.9 11.5 21.6 0.13
Mean BMI 27.3 27.2 27.3 0.33
Living alone, % 27.9 13.4 36.4 <0.01
Previous MI, % 8.6 5.8 10.2 0.36
Depression, % 26.4 23.1 28.4 0.49
Vessels involved, % 0.28
0 vessels 1.4 3.8 0
1 vessel 36.4 38.5 35.2
2 vessels 30.7 26.9 33.0
3 vessels 31.4 30.8 31.8
LVEF, % 47.4 47.6 47.3 0.89
Troponin T, μg/L 4.0 3.3 4.3 0.11
GRACE score 107.6 106.3 108.4 0.82
 Peak troponin T and lifetime depression are listed. BMI, body 
mass index; GRACE, Global Registry of Acute Coronary Events; 
LVEF, left ventricular ejection fraction; MI, myocardial infarction. 
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 Results 
 Patient Characteristics 
 Table 1 shows the patient characteristics of the total 
sample and both groups per pain level. The majority of 
patients were male. While few patients had had a previous 
MI, 1 out of 4 reported lifetime depression. The 2 groups 
did not differ significantly in age, gender distribution, 
and cardiac-related variables. Patients who experienced 
more pain were significantly more frequently living alone. 
 For illustrative purposes, cytokine values of both 
groups stratified according to the intensity of pain are 
shown in  Figure 1 . As shown in  Table 2 , most values were 
detectable.
 Regression Analysis 
 Table 3 shows hierarchical regression models includ-
ing the 4 cytokines as dependent variables.
 TNF-α. Only lifetime depression was significantly and 
inversely associated with TNF-α concentration ( p = 
0.013). No significant association emerged for pain with 
TNF-α ( p = 0.45).
 IL-6. Higher BMI ( p = 0.006) and a higher GRACE score 
( p = 0.003) were both associated with higher IL-6 concen-
trations. Pain was not associated with IL-6 ( p = 0.23).
 IL-33. Higher pain levels were significantly associated 
with lower IL-33 ( p = 0.015). Pain explained an addition-
al 4% of the variance in IL-33 concentration indepen-
dently of all other covariates in the model. None of the 
other variables were significantly associated with IL-33.
 Table 2.  Cytokine assessments
Results TNF-α IL-6 IL-33 TGF-β
Quantifiable, n 140 132 119 140
Not quantifiable, n 0 7 19 0
Not detectable, n 0 1 2 0
1,000
100
10
1
TN
F-
į,
 p
g/
m
L
5–7 8–10
10,000
1,000
100
10
1
0.1
IL
-6
, p
g/
m
L
60,000
40,000
20,000
0
TG
F-
Ǆ 1
, p
g/
m
L
10,000
1,000
100
10
1
0.1
IL
-3
3,
 p
g/
m
L
Pain score
5–7 8–10
Pain score
5–7 8–10
Pain score
5–7 8–10
Pain score
a b
c d
 Fig. 1. Box plots of serum levels of cytokines TNF-α (a), IL-6 (b), IL-33 (c), and TGF-β1 (d) grouped per less ver-
sus more intense pain (medians, interquartile ranges, whiskers at 5th and 95th percentiles). 
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 Table 3.  Regression analysis with TNF-α, IL-6, IL-33, and TGF-β1 as outcome variables
Step 1 Step 2 Step 3 Step 4 Step 5
TNF-α
Model statistics (n = 140)
ΔR2 0.014 0.057 0.004 0.011 0.004
p value 0.384 0.040 0.061 0.059 0.080
Age 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
Female gender –0.01 ± 0.05 0.03 ± 0.05 0.03 ± 0.05 0.03 ± 0.05 0.04 ± 0.05
Body mass index 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
Lifetime depression –0.11 ± 0.04 –0.12 ± 0.04 –0.11 ± 0.04 –0.11 ± 0.04
GRACE score 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
ASDS sum score –0.00 ± 0.00 –0.00 ± 0.00
Pain –0.01 ± 0.01
IL-6
Model statistics (n = 140)
ΔR2 0.044 0.032 0.068 0.004 0.009
p value 0.044 0.029 0.001 0.001 0.002
Age 0.01 ± 0.00 0.01 ± 0.00 –0.00 ± 0.01 –0.00 ± 0.01 –0.00 ± 0.01
Female gender –0.30 ± 0.13 –0.30 ± 0.13 –0.23 ± 0.13 –0.23 ± 0.13 –0.21 ± 0.13
Body mass index 0.02 ± 0.01 0.03 ± 0.01 0.03 ± 0.01 0.03 ± 0.01
Lifetime depression 0.11 ± 0.11 0.08 ± 0.11 0.07 ± 0.11 0.08 ± 0.11
GRACE score 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00
ASDS sum score 0.00 ± 0.01 0.00 ± 0.01
Pain –0.04 ± 0.03
IL-33
Model statistics (n = 140)
ΔR2 0.037 0.020 0.000 0.002 0.041
p value 0.075 0.092 0.158 0.225 0.047
Age –0.01 ± 0.01 –0.01 ± 0.01 –0.01 ± 0.01 –0.02 ± 0.01 –0.02 ± 0.01
Female gender – 0.04 ± 0.19 –0.09 ± 0.20 –0.10 ± 0.20 –0.10 ± 0.20 –0.05 ± 0.20
Body mass index –0.03 ± 0.02 –0.03 ± 0.02 –0.03 ± 0.02 –0.02 ± 0.02
Lifetime depression 0.06 ± 0.17 0.06 ± 0.17 0.08 ± 0.17 0.10 ± 0.17
GRACE score 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00
ASDS sum score –0.00 ± 0.01 –0.01 ± 0.01
Pain –0.11 ± 0.04
TGF-β1
Model statistics (n = 140)
ΔR2 0.066 0.024 0.003 0.001 0.029
p value 0.010 0.012 0.021 0.038 0.014
Age –147.38 ± 53.91 –127.59 ± 54.58 –159.49 ± 73.49 –163.26 ± 74.67 –160.43 ± 73.79
Female gender 3,127.67 ± 1,613.47 3,377.93 ± 1,659.54 3,560.01 ± 1,686.564 3,550.28 ± 1,692.54 3,234.27 ± 1,678.53
Body mass index 266.44 ± 140.78 289.01 ± 145.33 290.79 ± 145.92 268.98 ± 144.50
Lifetime depression 359.45 ± 1408.18 300.43 ± 1414.13 379.94 ± 1440.99 179.08 ± 1426.48
GRACE score 19.72 ± 30.35 21.87 ± 31.20 18.00 ± 30.87
ASDS sum score –18.78 ± 59.38 –3.73 ± 59.09
Pain 770.91 ± 369.95
 Data are shown as unstandardized b coefficients (means ± SEM). Results with p < 0.05 are in italics. ASDS, Acute Stress Disorder 
Scale; GRACE, Global Registry of Acute Coronary Events. Values <0.005 were approximated to 0.00.
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 TGF-β 1 . Higher pain levels were associated with a 
higher TGF-β 1 concentration ( p = 0.031), whereas older 
patients had lower TGF-β 1 ( p = 0.039). Pain explained an 
additional 2.9% of the variance in TGF-β 1 concentration, 
independently of all other covariates in the model.
 Discussion 
 The purpose of our study was to examine whether pain 
during AMI is related to inflammation, independent of 
demographic, medical, and psychometric factors. We 
found significant associations with levels of circulating 
anti-inflammatory cytokines but not with levels of proin-
flammatory cytokines.
 More intense pain during MI was significantly associ-
ated with lower IL-33 levels. To the best of our knowl-
edge, no study has previously examined circulating IL-33 
during AMI and its relationship to pain or acute psycho-
logical distress. Since IL-33 was shown to have cardiopro-
tective and anti-atherosclerotic properties in general  [11] , 
we interpret this relationship to reflect a path leading 
from more intense pain during AMI to poorer cardiac 
prognosis, although this assumption needs investigation 
in prospective studies. However, the potential conse-
quences of lower circulating IL-33 levels during AMI are 
not unequivocal. While 2 studies found no prognostic 
significance of IL-33  [38, 39] , 2 other studies in patients 
with STEMI reported increased mortality  [28] and in-
creased risk of recurrent MI  [27] among those with high 
IL-33 levels. Further research is needed to evaluate the 
significance of decreased IL-33 in MI patients experienc-
ing more pain.
 We found a significant direct association between pain 
and the TGF-β 1 concentration. Only one study has previ-
ously examined TGF-β during AMI and its prognostic 
significance  [40] . That study showed neither a difference 
in circulating TGF-β 1 concentrations between ACS pa-
tients and patients with stable coronary artery disease nor 
an association with recurrent MI and mortality. An in-
crease in TGF-β 1 during AMI with greater pain intensity 
can therefore be assumed to have no negative effect on 
prognosis. TGF-β is known to be a significant mediator 
of nociception and to have protective effects against the 
development of chronic neuropathic pain  [41] . The effect 
we found could therefore be part of a physiological coun-
terregulation set off by acute pain.
 We did not observe a significant association between 
pain and TNF-α during AMI. Since cardiac inflammation 
is also expected to produce TNF-α  [8] , a potential inde-
pendent effect of pain or ASD on TNF-α levels might be 
superimposed by the acute phase response launched by 
myocardial damage.
 We further found that neither pain nor ASD symp-
toms were significantly associated with IL-6 levels. A cor-
relation, however, was observed for the GRACE score. 
This is in line with the previous literature showing that 
IL-6 is associated with increased morbidity and mortality 
after ACS  [24–26] . We had hypothesized that pain or 
ASD would also be associated with IL-6, since it has pre-
viously been described as a predictor of posttraumatic 
stress disorder  [42] . However, such a relationship may be 
too subtle compared to superimposed cardiac inflamma-
tion.
 The characteristic course of the acute phase reaction 
during MI might be responsible for our nonsignificant 
results with regard to the proinflammatory cytokines. As 
mentioned above, cardiac inflammation during AMI can 
be divided in a first step, which is affected by proinflam-
matory cytokines and an inflammatory reaction to pro-
cess and clear damaged tissue, and a second step, in 
which inflammation is suppressed by anti-inflammatory 
cytokines in order to initiate myofibroblast proliferation 
and scarring  [7, 8] . It is possible that, due to the delay 
between onset of symptoms and blood sampling, we pri-
marily examined the second phase. Therefore, in our 
samples, proinflammatory cytokines may already have 
been downregulated by anti-inflammatory mediators 
and thereby escaped detection in relation to pain inten-
sity.
 Cytokines also showed associations with other demo-
graphic and medical variables. IL-6 was directly associ-
ated with BMI. This has been found previously in, for 
instance, the CoLaus study  [43] . TGF-β concentrations 
were lower in our younger study participants. Surpris-
ingly, patients with lifetime depression had lower concen-
trations of TNF-α during AMI, although major depres-
sive disorder has been associated with inflammation, in-
cluding higher levels of TNF-α  [44, 45] .
 Our data indicated that patients experiencing more 
pain were significantly more often living alone. Other de-
mographic variables, i.e., age, gender, and BMI, were not 
associated with pain. Cardiac markers like peak troponin 
value, the number of coronary vessels affected, left ven-
tricular ejection fraction, and the GRACE score did also 
not differ between both groups (high vs. low pain indica-
tions). Pain was therefore not primarily influenced by 
cardiac injury, an interpretation which is supported by 
previous data showing that chest pain considerably re-
lates to psychological factors  [46] .
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 Our study has several limitations. We measured cyto-
kine levels only once, which does not trace modeling of 
their trajectory during the acute phase of MI. Blood sam-
ples could be drawn within several days after MI onset, 
depending upon how quickly patients were admitted to 
the hospital and included in our study. Consequently, as 
cytokine concentrations change over time during AMI, 
our results were affected by the variability of the interval 
between onset of pain and blood sampling. Recall bias is 
possible, as, due to the study design, we assessed pain ret-
rospectively and only approached patients who were he-
modynamically stable, often after the acute coronary in-
tervention. We included patients who experienced a sig-
nificant amount of pain, which reduces the variability in 
pain scores and thus the chance of finding a significant 
association with cytokine levels, while also limiting gen-
eralizability of our results to patients with little or no pain. 
Due to the cross-sectional design of our study, we are un-
able to draw causal inferences. Cytokines have previously 
been discussed as transmitters of danger signals to the 
brain and thereby to induce sickness behavior  [47, 48] , 
and therefore an influence of cytokines on pain percep-
tion is also possible.
 In summary, our study suggests that cytokines during 
AMI are not only reacting to myocardial ischemic tissue 
damage, they are also connected to the subjective experi-
ence of the situation reflected by pain intensity. We found 
an association between acute pain levels and IL-33 and 
TGF-β, 2 predominantly anti-inflammatory cytokines, in 
a cohort of patients with AMI. To the best of our knowl-
edge, the currently available evidence does not allow a 
firm statement as to the clinical relevance in terms of in-
creased morbidity and mortality of the observed relation-
ships between pain and cytokine levels. However, as IL-33 
has well-established atheroprotective functions and is 
beneficial for cardiac remodeling, its decrease in conjunc-
tion with pain might worsen the prognosis of patients 
with cardiac disease.
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